Such a role in myocardial and pulmonary fibrosis could be particularly useful in treating heart failure and PAH where substantial fibrosis is known to occur in both organs (Murtha et al., 2017; Thenappan et al., 2018) and where apelin has already been identified as a potential therapeutic strategy. Here, APLN is linked to pulmonary arterial hypertension.